Construction of nanostructured DNA harbouring phosphorodiamidate morpholino oligonucleotide for controlled tissue distribution in mice

References

• Dirin M, Winkler J. Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides. Expert Opin Biol Ther. 2013;13:875–888.
   PubMed Web of Science ®Google Scholar
• Amantana A, Iversen PL. Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers. Curr Opin Pharmacol. 2005;5:550–555.
   PubMed Web of Science ®Google Scholar
• Lim KR, Maruyama R, Yokota T. Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Dev Ther. 2017;11:533–545.
   PubMed Web of Science ®Google Scholar
• Borgia G, Maraolo AE, Buonomo AR, et al. The therapeutic potential of new investigational hepatitis C virus translation inhibitors. Expert Opin Investig Drugs. 2016;10:1209–1214.
   Google Scholar
• Heald AE, Charleston JS, Iversen PL, et al. AVI-7288 for Marburg virus in nonhuman primates and humans. N Engl J Med. 2015;373:339–348.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA grants accelerated approval to first drug for Duchenne muscular dystrophy [press release]. Silver Spring (MD): FDA; 2016 [cited September 19]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm521263.htm
   Google Scholar
• Heemskerk H, de Winter C, van Kuik P, et al. Preclinical PK and PD studies on 2′-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol Ther. 2010;6:1210–1217.
   Google Scholar
• Cirak S, Arechavala-Gomeza V, Guglieri M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet. 2011;378:595–605.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services [Internet]. Drug Approval Package: Exondys 51 Injection (eteplirsen). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206488_TOC.cfm
   Google Scholar
• Morcos PA, Li Y, Jiang S. Vivo-morpholinos: a non-peptide transporter delivers morpholinos into a wide array of mouse tissues. BioTechniques. 2008;45:613–623.
   PubMed Web of Science ®Google Scholar
• Li Y-F, Morcos PA. Design and synthesis of dendritic molecular transporter that achieves efficient in vivo delivery of morpholino antisense oligo. Bioconjug Chem. 2008;19:1464–1470.
   PubMed Web of Science ®Google Scholar
• Lehto T, Ezzat K, Wood MJ, et al. Peptides for nucleic acid delivery. Adv Drug Deliv Rev. 2016;106:172–182.
   PubMed Web of Science ®Google Scholar
• Abes R, Arzumanov AA, Moulton HM, et al. Cell-penetrating-peptide-based delivery of oligonucleotides: an overview. Biochem Soc Trans. 2007;35:775–779.
   PubMed Web of Science ®Google Scholar
• Bhadra J, Pattanayak S, Khan PP, et al. Internal oligoguanidinium-based cellular transporter enhances antisense efficacy of morpholinos in in vitro and zebrafish model. Bioconjug Chem. 2016;27:2254–2259.
   PubMed Web of Science ®Google Scholar
• Ming X, Carver K, Wu L. Albumin-based nanoconjugates for targeted delivery of therapeutic oligonucleotides. Biomaterials. 2013;34:7939–7949.
   PubMed Web of Science ®Google Scholar
• Ming X, Wu L, Carver K, et al. Dendritic nanoconjugates for intracellular delivery of neutral oligonucleotides. Nanoscale. 2015;7:12302–12306.
   PubMed Web of Science ®Google Scholar
• Gebski BL, Mann CJ, Fletcher S, et al. Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum Mol Genet. 2003;12:1801–1811.
   PubMed Web of Science ®Google Scholar
• Popplewell LJ, Abu-Dayya A, Khanna T, et al. Novel cationic carotenoid lipids as delivery vectors of antisense oligonucleotides for exon skipping in Duchenne muscular dystrophy. Molecules. 2012;17:1138–1148.
   PubMed Web of Science ®Google Scholar
• Mohri K, Takahashi N, Nishikawa M, et al. Increased immunostimulatory activity of polypod-like structured DNA by ligation of the terminal loop structures. J Control Release. 2012;163:285–292.
   PubMed Web of Science ®Google Scholar
• Mohri K, Nishikawa M, Takahashi N, et al. Design and development of nanosized DNA assemblies in polypod-like structures as efficient vehicles for immunostimulatory CpG motifs to immune cells. ACS Nano. 2012;6:5931–5940.
   PubMed Web of Science ®Google Scholar
• Nishikawa M, Matono M, Rattanakiat S, et al. Enhanced immunostimulatory activity of oligodeoxynucleotides by Y-shape formation. Immunology. 2008;124:247–255.
   PubMed Web of Science ®Google Scholar
• Uno S, Nishikawa M, Mohri K, et al. Efficient delivery of immunostimulatory DNA to mouse and human immune cells through the construction of polypod-like structured DNA. Nanomedicine. 2014;10:765–774.
   PubMed Web of Science ®Google Scholar
• Nishikawa M, Ogawa K, Umeki Y, et al. Injectable, self-gelling, biodegradable, and immunomodulatory DNA hydrogel for antigen delivery. J Control Release. 2014;180:25–32.
   PubMed Web of Science ®Google Scholar
• Graziewicz MA, Tarrant TK, Buckley B, et al. An endogenous TNF-alpha antagonist induced by splice-switching oligonucleotides reduces inflammation in hepatitis and arthritis mouse models. Mol Ther. 2008;16:1316–1322.
   PubMed Web of Science ®Google Scholar
• Zalutsky MR, Narula AS. A method for the radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodine. Int J Rad Appl Instrum A. 1987;38:1051–1055.
   PubMedGoogle Scholar
• Nishikawa M, Takemura S, Takakura Y, et al. Targeted delivery of plasmid DNA to hepatocytes in vivo: optimization of the pharmacokinetics of plasmid DNA/galactosylated poly(l-lysine) complexes by controlling their physicochemical properties. J Pharmacol Exp Ther. 1998;287:408–415.
   PubMed Web of Science ®Google Scholar
• Kawabata K, Takakura Y, Hashida M. The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake. Pharm Res. 1995;12:825–830.
   PubMed Web of Science ®Google Scholar
• Nishikawa M, Nakano T, Okabe T, et al. Residualizing indium-111-radiolabel for plasmid DNA and its application to tissue distribution study. Bioconjug Chem. 2003;14:955–961.
   PubMed Web of Science ®Google Scholar
• Christensen EI, Birn H, Storm T, et al. Endocytic receptors in the renal proximal tubule. Physiology (Bethesda). 2012;27:223–236.
   PubMed Web of Science ®Google Scholar
• King FG, Dedrick RL. Pharmacokinetic model for 2-amino-1,3,4-thiadiazole in mouse, dog, and monkey. Cancer Treat Rep. 1979;63:1939–1947.
   PubMedGoogle Scholar
• Takagi T, Hashiguchi M, Mahato RI, et al. Involvement of specific mechanism in plasmid DNA uptake by mouse peritoneal macrophages. Biochem Biophys Res Commun. 1998;245:729–733.
   PubMed Web of Science ®Google Scholar
• Geary RS, Watanabe TA, Truong L, et al. Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J Pharmacol Exp Ther. 2001;296:890–897.
   PubMed Web of Science ®Google Scholar
• McMahon BM, Mays D, Lipsky J, et al. Pharmacokinetics and tissue distribution of a peptide nucleic acid after intravenous administration. Antisense Nucleic Acid Drug Dev. 2002;12:65–70.
   PubMedGoogle Scholar
• Carver MP, Charleston JS, Shanks C, et al. Toxicological characterization of exon skipping phosphorodiamidate morpholino oligomers (PMOs) in non-human primates. JND. 2016;3:381–393.
   Google Scholar
• Ferguson DP, Dangott LJ, Lightfoot JT. Lessons learned from vivo-morpholinos: how to avoid vivo-morpholino toxicity. Biotechniques. 2014;56:251–256.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Maezawa T, Araie Y, et al. In vitro and in vivo stimulation of toll-like receptor 9 by CpG oligodeoxynucleotides incorporated into polypod-like DNA nanostructures. J Pharm Sci. 2017;106:2457–2462.
   PubMed Web of Science ®Google Scholar